Cash-pay telehealth has spent the last few years learning a hard lesson: patient demand can move much faster than the infrastructure built to support it.
GLP-1 medications transformed virtual care almost overnight. Patients wanted faster, more affordable access to treatment, while healthcare organizations raced to scale clinical operations, pharmacy partnerships , and digital workflows. As demand grew, so did regulatory scrutiny, which showed how much it matters to build systems that can adapt.
Now attention is turning to peptides.
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptide-related substances for possible inclusion on the 503A Bulks List, the list of ingredients state-licensed pharmacies may use to compound. The committee recommended six of them, against the advice of FDA staff, and rejected one. The FDA has not yet acted on those recommendations, and none of the peptides is FDA-approved.
For healthcare organizations, the bigger takeaway is not just about peptides. It is about preparing for emerging therapies while the rules are still being written.
Lessons From the GLP-1 Boom
The rise of GLP-1s showed how quickly organizations can end up balancing patient demand against operational complexity.
As compounded GLP-1s gained popularity, providers, pharmacies, and telehealth companies had to adapt to shifting regulations, changing supply chains, and growing oversight. In 2026 alone, the FDA sent 30 warning letters to telehealth companies over how they marketed compounded GLP-1s, and in April it proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, which would block large-scale outsourcing facilities from compounding them from bulk ingredients.
The lesson reaches well beyond weight loss. As new treatment categories emerge, organizations need operations that can evolve with changing clinical and regulatory expectations.
What the FDA Panel Decided
Interest in peptides keeps growing, and so does regulatory attention. Here is how the PCAC review played out:
Most votes were close; BPC-157 passed 8–6 with one abstention, and DSIP failed by a single vote. FDA staff had recommended against adding any of the seven.
The recommendations are advisory. The FDA still has to decide whether to act on them through rulemaking, and a place on the list would not mean FDA approval or validate broader wellness or longevity claims.
For operators, this window is an opportunity to check whether internal processes can support emerging therapies responsibly, whichever way the final decision goes.
Peptide
Reviewed
Committee recommendation
BPC-157
July 23
Add to 503A Bulks List
KPV
July 23
Add to 503A Bulks List
TB-500
July 23
Add to 503A Bulks List
MOTS-c
July 23
Add to 503A Bulks List
Semax
July 24
Add to 503A Bulks List
Epitalon
July 24
Add to 503A Bulks List
DSIP (emideltide)
July 24
Do not add
Operational Readiness Is the Real Differentiator
Introducing a new treatment category takes much more than adding another product to a website. Organizations should ask whether their operations can support:
- Appropriate clinical evaluation and provider oversight
- Clear, accurate patient education and communication
- Coordination between providers, pharmacies, and care teams
- Scalable workflows that adapt as regulations evolve
Strong infrastructure does more than support compliance. It creates a more consistent patient experience and lets organizations respond faster as healthcare changes.
Looking Ahead
The FDA's peptide review will not answer every question about compounded peptides, but it is an important milestone in a fast-moving area of care.
Whether the next wave centers on peptides , GLP-1s, or another emerging therapy, organizations that invest in scalable workflows, connected care teams, and adaptable systems will be better equipped for what comes next.
Success will depend less on reacting to regulatory change and more on having the infrastructure to adapt quickly. Whether you are supporting GLP-1 programs today or peptide therapies tomorrow, you need telehealth infrastructure built for flexibility , connected workflows, and long-term scale. That is where modern healthcare infrastructure becomes a competitive advantage.
Preparing for what comes after GLP-1s? Get Started.
Ready to own your stack?
See how Telegra's infrastructure keeps operations running when regulations shift.